{"id":"zelapar","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Rhinitis","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Stomatitis","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Dysphagia","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Flatulence","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Tooth Disorder","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Leg Cramps","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Dry Mouth","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Hallucinations","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Somnolence","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Tremor","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Ataxia","drugRate":"2%","severity":"common","organSystem":""}],"contraindications":["Angina pectoris","Bipolar disorder","Conduction disorder of the heart","Disease of liver","Kidney disease","Malignant melanoma","Mania","Orthostatic hypotension","Pheochromocytoma","Psychotic disorder","Suicidal thoughts","Tardive dyskinesia"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Chest Pain","drugRate":"2%","severity":"serious"},{"effect":"Dyskinesia","drugRate":"3%","severity":"serious"},{"effect":"Dyspnea","drugRate":"3%","severity":"serious"},{"effect":"Rash","drugRate":"3%","severity":"serious"},{"effect":"Skin Disorders","drugRate":"4%","severity":"serious"},{"effect":"Hypertension","drugRate":"1%","severity":"serious"},{"effect":"Ecchymosis","drugRate":"2%","severity":"serious"},{"effect":"Hypokalemia","drugRate":"2%","severity":"serious"},{"effect":"Depression","drugRate":"1%","severity":"serious"},{"effect":"Pharyngitis","drugRate":"2%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL972","moleculeType":"Small molecule","molecularWeight":"187.29"},"aliases":["orally disintegrating selegiline"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"380d7717-2a79-42f3-a712-efe5e7696ba0","title":"ZELAPAR (SELEGILINE HYDROCHLORIDE) TABLET, ORALLY DISINTEGRATING [BAUSCH HEALTH US, LLC]"},"ecosystem":[],"mechanism":{"target":"Alpha-synuclein, Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor"},"_scrapedAt":"2026-03-28T00:16:27.201Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Major depressive disorder","diseaseId":"major-depressive-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Parkinson's disease","diseaseId":"parkinson's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07452692","phase":"PHASE1","title":"A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Corium Innovations, Inc.","startDate":"2026-07-01","conditions":"Major Depressive Disorder (MDD)","enrollment":230},{"nctId":"NCT06607744","phase":"","title":"Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects","status":"COMPLETED","sponsor":"Corium Innovations, Inc.","startDate":"2025-02-10","conditions":"MDD","enrollment":12},{"nctId":"NCT00640159","phase":"PHASE4","title":"Selegiline to Zelapar Switch Study in Parkinson Disease Patients","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2007-01","conditions":"Parkinson's Disease","enrollment":48},{"nctId":"NCT05938517","phase":"PHASE1","title":"Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2021-06-02","conditions":"Ménière's Disease","enrollment":15},{"nctId":"NCT00013585","phase":"PHASE2","title":"Safety and Effectiveness of the Selegiline \"Patch\" for Decreased Mental Function in HIV Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Cognition Disorders, HIV Infections","enrollment":127},{"nctId":"NCT04968613","phase":"PHASE4","title":"Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2018-01-01","conditions":"Parkinson Disease, Memory Impairment","enrollment":150},{"nctId":"NCT04870372","phase":"PHASE4","title":"Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2020-03-01","conditions":"Parkinson Disease","enrollment":141},{"nctId":"NCT04586543","phase":"PHASE2","title":"Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma","status":"UNKNOWN","sponsor":"László Mangel","startDate":"2020-05-18","conditions":"Metastatic Castration-resistant Prostate Cancer, Adenocarcinoma of the Prostate","enrollment":110},{"nctId":"NCT04130087","phase":"NA","title":"Selegiline and Reward Processing","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2019-09-18","conditions":"Healthy","enrollment":54},{"nctId":"NCT02225548","phase":"PHASE4","title":"Sagene 2014 - Parkinson's Disease and Erectile Dysfunction","status":"UNKNOWN","sponsor":"University of South Florida","startDate":"2014-09","conditions":"Parkinson's Disease, Erectile Dysfunction","enrollment":10},{"nctId":"NCT00282152","phase":"NA","title":"Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2006-03","conditions":"Parkinson's Disease","enrollment":37},{"nctId":"NCT00439413","phase":"PHASE2","title":"Selegiline for Smoking Cessation - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2007-06","conditions":"Nicotine Dependence","enrollment":246},{"nctId":"NCT00000336","phase":"PHASE2","title":"Selegiline in Outpatient Treatment for Cocaine Dependence - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1995-01","conditions":"Cocaine-Related Disorders","enrollment":""},{"nctId":"NCT00000337","phase":"PHASE1","title":"Infusion Laboratory: Protocol 1 - Selegeline - 2","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1994-11","conditions":"Cocaine-Related Disorders","enrollment":""},{"nctId":"NCT00218517","phase":"PHASE2","title":"Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2005-03","conditions":"Marijuana Abuse","enrollment":19},{"nctId":"NCT00032929","phase":"PHASE3","title":"Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-03","conditions":"Cocaine-Related Disorders","enrollment":269},{"nctId":"NCT00000201","phase":"PHASE2","title":"Pharmacological Modulation of Cocaine Effects - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"","conditions":"Cocaine-Related Disorders","enrollment":""},{"nctId":"NCT00033072","phase":"PHASE1","title":"Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1","status":"UNKNOWN","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-09","conditions":"Amphetamine-Related Disorders","enrollment":16},{"nctId":"NCT01701089","phase":"PHASE1","title":"A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-09","conditions":"Healthy Volunteer, Alzheimer's Disease","enrollment":17},{"nctId":"NCT01330030","phase":"PHASE2","title":"Selegiline Patch for Treatment of Nicotine Dependence","status":"COMPLETED","sponsor":"Stanford University","startDate":"2005-07","conditions":"Tobacco Use Disorder","enrollment":243},{"nctId":"NCT01912391","phase":"PHASE3","title":"Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder","status":"COMPLETED","sponsor":"Mood and Anxiety Research, Inc","startDate":"2012-10","conditions":"Borderline Personality Disorder","enrollment":30},{"nctId":"NCT00000188","phase":"PHASE2","title":"Selegiline in Treatment of Cocaine Dependence - 2","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"1994-09","conditions":"Cocaine-Related Disorders","enrollment":50},{"nctId":"NCT00129311","phase":"PHASE2","title":"Usefulness of Selegiline as an Aid to Quit Smoking - 1","status":"COMPLETED","sponsor":"Yale University","startDate":"2004-07","conditions":"Tobacco Use Cessation","enrollment":101},{"nctId":"NCT00027040","phase":"NA","title":"A Study of Decreased Mental Function Associated With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Cognitive Disorders, HIV Infections","enrollment":90},{"nctId":"NCT00443872","phase":"PHASE4","title":"Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists","status":"COMPLETED","sponsor":"Parkinson's Disease and Movement Disorder Center of Boca Raton","startDate":"2007-03","conditions":"Parkinson's Disease","enrollment":77},{"nctId":"NCT00535262","phase":"PHASE4","title":"A Pilot Study Assessing EmSam in Bipolar Depression","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2007-03","conditions":"Bipolar Depression","enrollment":3},{"nctId":"NCT00531947","phase":"PHASE4","title":"Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression","status":"COMPLETED","sponsor":"Somerset Pharmaceuticals","startDate":"2007-07","conditions":"Major Depressive Disorder","enrollment":308},{"nctId":"NCT01495195","phase":"PHASE2","title":"Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior","status":"COMPLETED","sponsor":"Midwest Biomedical Research Foundation","startDate":"2012-02","conditions":"Cocaine Use Disorders","enrollment":12},{"nctId":"NCT00390923","phase":"NA","title":"Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence","status":"TERMINATED","sponsor":"Centre for Addiction and Mental Health","startDate":"2007-07","conditions":"Nicotine Dependence","enrollment":40},{"nctId":"NCT00456976","phase":"EARLY_PHASE1","title":"Efficacy of Selegiline in Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"Tabriz University","startDate":"2007-04","conditions":"Schizophrenia","enrollment":70},{"nctId":"NCT00285766","phase":"PHASE3","title":"Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression","status":"COMPLETED","sponsor":"Somerset Pharmaceuticals","startDate":"2002-08","conditions":"Major Depression","enrollment":300},{"nctId":"NCT00532116","phase":"PHASE4","title":"PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly","status":"COMPLETED","sponsor":"Somerset Pharmaceuticals","startDate":"2007-04","conditions":"Healthy","enrollment":32},{"nctId":"NCT00531596","phase":"PHASE4","title":"Evaluation of Adhesion and Dermal Tolerability of EMSAM","status":"COMPLETED","sponsor":"Somerset Pharmaceuticals","startDate":"2007-04","conditions":"Healthy","enrollment":300},{"nctId":"NCT00002154","phase":"PHASE2","title":"A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia","status":"COMPLETED","sponsor":"The Dana Foundation","startDate":"","conditions":"Cognitive Disorders, HIV Infections","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20210616","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA021479"},{"date":"20060614","type":"ORIG","sponsor":"BAUSCH","applicationNumber":"NDA021479"},{"date":"20151009","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA021479"},{"date":"20140731","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA021479"},{"date":"20081231","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA021479"},{"date":"20190819","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA021479"},{"date":"20081231","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA021479"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Zelapar","genericName":"Zelapar","companyName":"Baylor College of Medicine","companyId":"baylor-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}